

Stabilis



Adalimumab



Tradename

Amgevita	Belgium, Chile, France, Germany, Great Britain
Humira	Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, Ecuador, Finland, France, Germany, Great Britain, Greece, Iceland, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Romania, Saudi Arabia, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, United States of America, Venezuela
Imraldi	Belgium, Great Britain, Spain
Truxeda	Austria, Belgium, Denmark, Finland, Germany, Greece, Iceland, Japan, Poland, Sweden



Stability in solutions

		50 mg/ml	23-27°C		28			4627






















References

	Type	Publication
4627	Journal	Park D, Yun J, Hwang S-J, Park SJ. Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature. Adv Ther 2019 36:442-450



Dictionary

 Immunosuppressant	 Injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration
 Biosimilar	 Conflicting data
 References	 Polypropylen Syringe
 None	 Light
 Day	 References
 Dictionary	